Zúñiga RNE, Ponce RER, Jiménez GI, Acevedo GO, Vicenteño AH

Language: Spanish
References: 15
Page: 55-63
PDF size: 171.56 Kb.

ABSTRACT

Objective: To determine plasma levels of cC in patients with Diabetes Mellitus. Methods: Study Design: prospective, cross-sectional, comparative and observational. Sample: nonrandom, 111 patients with type 2 diabetes, two groups: hospital and clinic, outpatient. Variables: measurement of renal function and metabolic control partners. Measurement: serum determinations of cC. Analysis: descriptive and inferential (student T test, U of Mann-Whitney). Pearson correlation. Results: There were significant differences in values for cC in patients with adequate metabolic control and in the clinic compared with hospital: Glycosylated hemoglobin (p = 0.015), total cholesterol (p = 0.030) and triglycerides (p = 0.001). Moderate inverse association between cC and creatinine clearance (Pearson correlation = - .436, p = 0.018). Conclusions: The age and metabolic control are important markers for determining initial kidney damage in asymptomatic patients. cC is a prognostic marker of early renal damage in patients with type 2 diabetes, compared with the gold standard (creatinine clearance).

REFERENCES

1. Martínez-Brú C. Cistatina C. Propiedades y utilidad clínica. Ed Cont Lab Clin 2006; 9: 36-41.

2. Sánchez C, Fernández V. Diabetes Mellitus 2. Metodología en atención primaria. Centro de atención primaria, España 2010.

3. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2013; 36. Supplement 1.

4. Jun-Yoon C, Sung-Hoon P, Seong-Kyu K. Serum Cystatin C is a potential endogenous marker for the estimation of renal function in male gout patients with renal impairment. J Korean Med Sci 2010; 25: 42-8.

5. White C, Akbari A, Hussain N, Dinh L, Filler G, Lepage N, Knoll GA. Estimating glomerular filtration rate in kidney transplantation: A comparison between serum creatinine and cystatin C – based methods. J Am Soc Nephrol 2005;16: 3763 – 3770.

6. Badimón JJ, Santos – Gallego CG, Kaski JJ, Castillo J, Torres F. Nuevas herramientas en la estratificación del riesgo cardiovascular. Rev Esp Cardiol Supl 2011; 11(B): 21-28.

7. Rodríguez LM, Roglan PA. Diagnóstico precoz del fracaso renal agudo. Med Intensiva 2010; 34 (5): 291-293.

8. Arias MA, Pobes A, Baños M. Cistatina C. Nuevo marcador de la función renal. Nefrología 2005; 5 (3): 217-220.

9. Spanaus KS, Kollerits B, Ritz E, Hersberger M. Serum creatinine, Cystatin C and β – Trace protein in diagnostic staging and predicting progression of primary nondiabetic chronic kidney disease. Clinical Chemistry 2010; 56 (5): 740-749.

10. Martínez Islas KH, Domínguez JS. Utilidad clínica de la Cistatina C como marcador de función renal. An Med Asoc Med Hosp ABC 2003; 48 (4): 216-222.

11. Mussap M, Vestra MD, Fioretto P, Saller A, Varagnolo MC, Nosadini R.Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney International 2002; 61: 1453-1461.

12. Sun Yang Y, Peng CH, Lin CK, Wang CP, Huang CN.Use of serum Cystatin C to detect early decline of glomerular filtration rate in type 2 diabetes. Internal Medicine 2007; 46.6081: 801- 806.

13. Sarnak MJ, Katz R, Stehman-Breen CO, Fried LF, Swords NJ, Siscovick D. Cystatin C concentration as a risk factor for heart failure in older adults. Annals of Internal Medicine 2005; 142 (7): 497-506.

14. Coll E, Poch E, Saurina A, Vera M, Darnell A. Serum Cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. American Journal of Kidney Diseases 2000; 3 (1): 29-34.

15. Martín MV, Barroso S, Herráez O, De Sande F, Caravaca F. Cistatina C como estimador de la función renal en estadios avanzados de la enfermedad renal crónica. Nefrología 2006;26(4): 433-438 63